Severe infections in thalassaemic patients: prevalence and predisposing factors.
The incidence of infections among patients with thalassaemia and the role of risk factors for infection are uncertain. We studied the occurrence of infections necessitating hospitalisation in 92 homozygous beta-thalassaemia patients who had been followed longitudinally for decades, and investigated the role of potential risk factors for these infections. Pneumonia accounted for 26% of the infections and fever of unknown origin for 14%. Staphylococcus aureus was the major pathogen possibly related to injections associated with intensive chelation with deferoxamine. There was a significant increase in the rate of infection over time, notably after 15 years. Splenectomy correlated with the incidence of infection (P < 0.001) without being confounded by other variables and with highest frequencies of infections present after 10 years. A direct correlation between iron overload and infection was evident only before the initiation of iron-chelating treatment (P < 0.01). Following initiation of deferoxamine, paradoxically, the infection rate increased (P = 0.046). The combination of splenectomy and deferoxamine treatment was associated with the highest adjusted infection rate. Parathyroid dysfunction and glucose-6-phosphate dehydrogenase deficiency were significantly associated with infection (P = 0.02 and P = 0.04 respectively). The infection rate in thalassaemia is affected mainly by the duration of the disease and is increased by splenectomy and, in the long term, by treatment with deferoxamine.
Rahav
Galia
G
Department of Clinical Microbiology and Infectious Diseases, Hadassah Medical Centre and School of Medicine, The Hebrew University, Ein-Kerem, Jerusalem, Israel. galia.rahav@sheba.health.gov.il
Volach
Vania
V
Shapiro
Mervyn
M
Rund
Deborah
D
Rachmilewitz
Eliezer A
EA
Goldfarb
Ada
A
D000293:Adolescent; D000328:Adult; D001424:Bacterial Infections / Q000209:etiology*; D002648:Child; D003676:Deferoxamine / Q000009:adverse effects / Q000627:therapeutic use; D005260:Female; D005293:Ferritins / Q000097:blood; D006760:Hospitalization; D006801:Humans; D019190:Iron Overload / Q000150:complications; D008137:Longitudinal Studies; D008297:Male; D009894:Opportunistic Infections / Q000209:etiology; D011184:Postoperative Period; D012307:Risk Factors; D017262:Siderophores / Q000009:adverse effects / Q000627:therapeutic use; D013156:Splenectomy / Q000009:adverse effects; D017086:beta-Thalassemia / Q000150:complications* / Q000188:drug therapy / Q000601:surgery
D017262:Siderophores; D005293:Ferritins; D003676:Deferoxamine